Predictive Value of Pretreatment Neutrophil to Albumin Ratio in Response to Neoadjuvant Chemotherapy of Breast Cancer

Figures & data

Table 1 Clinicopathologic Features of Patients Involved in This Study

Characteristics		Total n=212 (%)
Age (years)	≤50	143 (67.5)
	>50	69 (32.5)
cT stage	1	12 (5.7)
	2	158 (74.5)
	3	30 (14.2)
	4	12 (5.7)
cN stage	0	42 (19.8)
	1	123 (58.0)
	2	6 (2.8)
	3	41 (19.3)
Hormone Receptor (HR)	Positive	151 (71.2)
	Negative	61 (28.8)
HER2	Positive	92 (43.4)
	Negative	120 (56.6)
Ki-67	≤14%	12 (5.7)
	>14%	200 (94.3)
Molecular subtype	Luminal A	9 (4.2)
	Luminal B	85 (40.1)
	HER2 enriched (HR+)	57 (26.9)
	HER2 enriched (HR-)	35 (16.5)
	Triple Negative	26 (12.3)
Chemotherapy regimen	Anthracycline and Taxane	121 (57.1)
	Chemo + Trastuzumab +Pertuzumab	91 (42.9)
pCR	Yes	62 (29.2)
	No	150 (70.8)

Table 2 Relationships Between NAR and Patient Characteristics

Characteristics		NAR (n=212)
		≤0.0877 (n=98), n (%)	>0.0877 (n=114), n (%)	p value
Age (years)	≤50	73 (51.0)	70 (49.0)	0.043
	>50	25 (36.2)	44 (63.8)
cT stage	1–2	81 (47.6)	89 (52.4)	0.404
	3–4	17 (40.5)	25 (59.5)
cN stage	0	24 (57.1)	18 (42.9)	0.113
	1–3	74 (43.5)	96 (56.5)
Hormone Receptor (HR)	Negative	27 (44.3)	34 (55.7)	0.715
	Positive	71 (47.0)	80 (53.0)
HER2	Negative	65 (54.2)	55 (45.8)	0.008
	Positive	33 (35.9)	59 (64.1)
Ki-67	≤14%	9 (64.3)	5 (35.7)	0.161
	>14%	89 (44.9)	109 (55.1)
Chemotherapy regimen	Anthracycline and Taxane	65 (53.7)	56 (46.3)	0.012
	Chemo + Anti HER2	33 (36.3)	58 (63.7)

Table 3 Relationships Between pCR and Patient Characteristics

		Non pCR (n=150), n (%)	pCR (n=62), n (%)	p value
Age (years)	≤50	103 (72.0)	40 (28.0)	0.557
	>50	47 (68.1)	22 (31.9)
cT stage	1–2	125 (73.5)	45 (26.5)	0.074
	3–4	25 (59.5)	17 (40.5)
cN stage	0	26 (61.9)	16 (38.1)	0.159
	1–3	124 (72.9)	46 (27.1)
Hormone Receptor (HR)	Negative	33 (54.1)	28 (45.9)	0.001
	Positive	117 (77.5)	34 (22.5)
HER2	Negative	102 (85.0)	18 (15.0)	<0.001
	Positive	48 (52.2)	44 (47.8)
Ki-67	≤14%	12 (85.7)	2 (14.3)	0.175
	>14%	138 (69.7)	60 (30.3)
Chemotherapy regimen	Anthracycline and Taxane	103 (85.1)	18 (14.9)	<0.001
	Chemo + Anti HER2	47 (51.6)	44 (48.4)
NAR	≤0.0877	82 (83.7)	16 (16.3)	<0.001
	>0.0877	68 (59.6)	46 (40.4)

Figure 1 Receiver operating characteristic curve for determination of the cut-off value for the NAR in patients with breast cancer with NAC.

Figure 2 NAR values for non-pCR vs patients with pCR. Dashed lines represent the median, while dotted lines indicate the interquartile range.

Table 4 Association of Patient/Tumor Characteristics to pCR in Univariate and Multivariate Analysis

Variable	Univariate Analysis		Multivariate Analysis
	OR (95% CI)	p value	OR (95% CI)	p value
Age (years)
≤50	1 (Reference)	–
>50	1.205 (0.646–2.250)	0.558
cT stage
T1-2	1 (Reference)	-
T3-4	1.889 (0.934–3.819)	0.077
cN stage
N+	1 (Reference)	-
N0	0.603 (0.297–1.225)	0.162
Hormone Receptor (HR)
Negative	1 (Reference)	-	1 (Reference)	-
Positive	0.342 (0.182–0.644)	<0.001	0.396 (0.196–0.799)	0.010
HER2
Negative	1 (Reference)	-	-	-
Positive	5.194 (2.720–9.919)	<0.001	-	0.632
Ki-67
≤14%	1 (Reference)	-
>14%	2.609 (0.566–12.015)	0.219
Chemotherapy regimen
Chemo only	1 (Reference)	-	1 (Reference)	-
Chemo + Anti HER2	5.357 (2.803–10.240)	<0.001	4.326 (2.198–8.515)	<0.001
NAR
≤0.0877	1 (Reference)	-	1 (Reference)	-
>0.0877	3.467 (1.804–6.664)	<0.001	3.127 (1.545–6.328)	0.002

Notes: P-value; in logistic regression analysis, variables found to be statistically significant (p < 0.05) in univariate analysis were entered into a logistic regression multivariate model using a forward conditional method.

Abbreviations: OR, odds ratio; CI, confidence interval.

Data Sharing Statement

The original contributions presented in the study are included in the article material, further inquiries can be directed to the corresponding author.